Fig. 1From: Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitiscANCA/PR3 levels in the last 15 years of treatment. The dotted line indicates the upper limit of the reached cANCA/PR3, the blue line indicates the upper limit of the normal range for cANCA/PR3. RTX rituximab, IFX infliximab, AZA azathioprinBack to article page